Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma

Metabolomics analysis possibly identifies new therapeutic targets in treatment resistance by measuring changes in metabolites accompanying cancer progression. We previously conducted a global metabolomics (G-Met) study of renal cell carcinoma (RCC) and identified metabolites that may be involved in...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Tomonori Sato, Yoshihide Kawasaki, Masamitsu Maekawa, Shinya Takasaki, Kento Morozumi, Masahiko Sato, Shuichi Shimada, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Nariyasu Mano, Akihiro Ito
Formato:	Artigo
Idioma:	English
Publicado em:	MDPI AG 2020-12-01
coleção:	Metabolites
Assuntos:	metabolomics resistance renal cell carcinoma sunitinib glutamine
Acesso em linha:	https://www.mdpi.com/2218-1989/11/1/1

Registros relacionados

Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism
por: Kento Morozumi, et al.
Publicado em: (2024-03-01)

Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells
por: Miaki Uzu, et al.
Publicado em: (2015-05-01)

Potential for use sunitinib in pancreatic neuroendocrine tumors
por: A. A. Markovich, et al.
Publicado em: (2019-06-01)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa Takeshi, et al.
Publicado em: (2013-01-01)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
por: M'rabti Hind, et al.
Publicado em: (2011-07-01)

Pneumatosis cystoides intestinalis associated with sunitinib and a literature review
por: Yong Suk Lee, et al.
Publicado em: (2017-11-01)

Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma
por: Hiroyuki Shikuma, et al.
Publicado em: (2019-11-01)

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
por: Enrique Grande, et al.
Publicado em: (2013-01-01)

Sunitinib-Induced Acute Liver Failure
por: Anum Aqsa, et al.
Publicado em: (2021-01-01)

Sunitinib resistance in renal cell carcinoma
por: Christudas Morais
Publicado em: (2014-04-01)

Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells
por: Jun Ito, et al.
Publicado em: (2023-08-01)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Akihiro Yoshimura, et al.
Publicado em: (2020-09-01)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
por: Keyvanjah Kiana, et al.
Publicado em: (2012-08-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
por: Se Woong Choi, et al.
Publicado em: (2020-02-01)

Development and validation of a HPTLC method for analysis of Sunitinib malate
por: Monireh Hajmalek, et al.

Sunitinib for adenocarcinoma of the rete testis: a case report
por: Kezhen Li, et al.
Publicado em: (2024-04-01)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Kosmas Daskalakis, et al.
Publicado em: (2019-05-01)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maud Maillard, et al.
Publicado em: (2022-09-01)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
por: Alexandra Karadimou, et al.
Publicado em: (2011-08-01)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
por: Joan Manel Gasent Blesa, et al.
Publicado em: (2009-12-01)

Sunitinib in pancreatic neuroendocrine tumors. Clinical case
por: A. A. Markovich, et al.
Publicado em: (2019-12-01)

Impact of Sunitinib on Human Thyroid Cancer Cells
por: Jirka Grosse, et al.
Publicado em: (2013-07-01)

High throughput LC/ESI-MS/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma
por: Tensei Hirasawa, et al.
Publicado em: (2023-06-01)

Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids
por: Atthapol Srimongkol, et al.
Publicado em: (2023-02-01)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
por: Ying-Shou Chen, et al.
Publicado em: (2009-10-01)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats
por: Mohammad Nasser Hashemian, et al.
Publicado em: (2017-01-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
por: Giovanni Luca Gravina, et al.
Publicado em: (2017-01-01)

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
por: Romualdo Barroso-Sousa, et al.
Publicado em: (2014-12-01)

Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases
por: Schem Christian, et al.
Publicado em: (2013-01-01)

Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: Report of a case and literature review of kinase inhibitors and blocking antibodies
por: Shuchi Bansal, et al.
Publicado em: (2014-01-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Jun Guo, et al.
Publicado em: (2018-05-01)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Yun Peng, et al.
Publicado em: (2021-10-01)

Sunitinib induced hepatotoxicity in L02 cells via ROS-MAPKs signaling pathway
por: Ting-Li Tang, et al.
Publicado em: (2022-10-01)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
por: Pavla Bouchalova, et al.
Publicado em: (2021-09-01)

Sunitinib-Induced Adrenal Crisis in a Patient with Pre-Existing Immunotherapy-Related Hypopituitarism
por: Anadil Javaid, et al.
Publicado em: (2022-01-01)

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients
por: Michal Rihacek, et al.
Publicado em: (2022-06-01)

An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome
por: Veysel Haksöyler, et al.
Publicado em: (2021-06-01)

From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
por: Amal Kamal Abdel-Aziz, et al.
Publicado em: (2017-10-01)

Effect of isavuconazole on the pharmacokinetics of sunitinib and its mechanism
por: Jinyu Hu, et al.
Publicado em: (2024-09-01)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Çetin Ordu, et al.
Publicado em: (2016-06-01)